Clinical trials: Neuroblastoma in Children
Neuroblastoma
Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analog in treating children who have…
- Trial name
- NCT00003737
- Testing
- becatecarin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain Tumor, Central Nervous System Tumor
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
RATIONALE: Sodium thiosulfate may reduce or prevent hearing loss in young patients receiving cisplatin for cancer. It is not yet known whether sodium thiosulfate is more effective than no additional treatment in preventing…
- Conditions
- Brain Tumor, Central Nervous System Tumor, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
- Trial name
- NCT00716976
- Testing
- sodium thiosulfate, examination
- Where
- 76 sites in United States, Australia and 1 more
- Volunteers
- 131 people
- Sponsor
- Children's Oncology Group
Brain and Central Nervous System Tumors, Neuroblastoma
Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma
RATIONALE: Drugs such as temsirolimus and valproic acid may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT01204450
- Testing
- Temsirolimus, Valproic Acid
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Neuroblastoma
Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma
Neuroblastoma, the most common extra-cranial solid tumour in children, remains one of the major challenges in paediatric oncology.
- Trial name
- MiniVan (NCT02914405)
- Testing
- Nivolumab, Ch14.18/CHO
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Cancer
Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors
This study aims to determine the efficacy of daily sirolimus and celecoxib, with low dose etoposide alternating with cyclophosphamide for pediatric participants with relapsed or refractory tumors.
- Trial name
- AflacST1502 (NCT02574728)
- Testing
- Sirolimus, Celecoxib, Etoposide
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- Emory University
Neuroblastoma, Neuroblastoma (NB)
Fecal Microbiota Transplant for Neuroblastoma in a Single Patient
This study uses fecal microbiota transplant (FMT) to correct gut microbiome dysbiosis prior to and during standard-of-care neuroblastoma treatment
- Conditions
- Neuroblastoma, Neuroblastoma (NB), Neuroblastoma (NBL), Neuroblastoma (Measurable Disease)
- Trial name
- NCT07223606
- Testing
- Fecal Microbial Transplantation
- Where
- United States
- Sponsor
- ProgenaBiome
Disseminated Neuroblastoma, Recurrent Neuroblastoma
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
This phase II trial is studying how well ABT-751 works in treating children with neuroblastoma that has relapsed or not responded to previous treatment.
- Trial name
- NCT00436852
- Testing
- ABT-751, quality-of-life assessment
- Where
- 12 sites in United States, Canada
- Volunteers
- 92 people
- Sponsor
- Children's Oncology Group
Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor
Irinotecan in Treating Children With Refractory Solid Tumors
This phase II trial is studying irinotecan to see how well it works in treating children with refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Grade I Meningioma
- Trial name
- NCT00004078
- Testing
- irinotecan hydrochloride
- Where
- United States
- Volunteers
- 181 people
- Sponsor
- Children's Oncology Group
Neuroblastoma
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
- Trial name
- NCT04106219
- Testing
- LY3295668 Erbumine, Topotecan, Cyclophosphamide
- Where
- 17 sites in United States, Australia and 7 more
- Volunteers
- 71 people
- Sponsor
- Eli Lilly and Company
Neuroblastoma
Combination Chemotherapy in Treating Children With Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003093
- Testing
- filgrastim, sargramostim, carboplatin
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 573 people
- Sponsor
- Children's Oncology Group
Adult Rhabdomyosarcoma, Adult Synovial Sarcoma
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
This phase II trial is studying the side effects and how well cixutumumab works in treating patients with relapsed or refractory solid tumors. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways.
- Conditions
- Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Childhood Hepatoblastoma, Childhood Synovial Sarcoma
- Trial name
- NCT00831844
- Testing
- cixutumumab, laboratory biomarker analysis
- Where
- 105 sites in United States, Australia and 1 more
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Refractory or Recurrent Neuroblastoma in Children
Efficacy and Safety of Anlotinib, Irinotecan and Temozolomide in the Treatment of Refractory or Recurrent Neuroblastoma in Children: an Open, Single Arm, Single Center, Phase II Clinical Study
Neuroblastoma is an embryonal tumor originated from primitive neural crest cells. It is the most common extracranial solid tumor in children.
- Trial name
- NCT04842526
- Testing
- Anlotinib and irinotecan combined with temozolomide
- Volunteers
- 27 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Ependymoma, Ewing Sarcoma
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
The purpose of this study is to first, in Part A, assess the safety, tolerability and drug levels of Bempegaldesleukin (BEMPEG) in combination with nivolumab and then, in Part B, to estimate the preliminary efficacy in children…
- Conditions
- Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma
- Trial name
- PIVOT IO 020 (NCT04730349)
- Testing
- Nivolumab, NKTR-214
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Neuroblastoma
N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma
RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- IV Fenretinide (NCT00646230)
- Testing
- fenretinide, high performance liquid chromatography, pharmacological study
- Where
- 13 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Neuroblastoma
Chemotherapy in Treating Children With Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs.
- Trial name
- NCT00002730
- Testing
- buthionine sulfoximine, melphalan
- Where
- 4 sites in United States
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Ewing's Sarcoma, Osteosarcoma
Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
The best treatment for recurrent cancers or those that do not respond to therapies is not known. Typically, patients with these cancers receive a combination of cancer drugs (chemotherapy), surgery, or radiation therapy.
- Conditions
- Ewing's Sarcoma, Osteosarcoma, Astrocytoma, Atypical Teratoid/Rhabdoid Tumor
- Trial name
- Aflac ST0901 (NCT01331135)
- Testing
- sirolimus
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Emory University
Neuroblastoma Recurrent
CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma
A six courses regimen consisting of a 8 hour infusion (ch14.18/CHOmAb 20 mg/m²) for five consecutive days will be administered every 4 weeks, starting 60-180 days after previous haploidentical stem cell transplantation.
- Trial name
- NCT02258815
- Testing
- ch14.18/CHO
- Where
- 4 sites in Austria, Germany
- Volunteers
- 35 people
- Sponsor
- University Children's Hospital Tuebingen
Neuroblastoma
Surgery in Treating Children With Neuroblastoma
RATIONALE: Surgery alone may be effective in treating children with neuroblastoma. PURPOSE: Phase III trial to study the effectiveness of surgery alone in treating children who have neuroblastoma.
- Trial name
- NCT00003119
- Testing
- filgrastim, sargramostim, carboplatin
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 968 people
- Sponsor
- Children's Oncology Group
Pediatric Solid Tumor, Germ Cell Tumor
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of…
- Conditions
- Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma
- Trial name
- NCT04483778
- Testing
- second generation 4-1BBζ B7H3-EGFRt-DHFR, second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG, Pembrolizumab
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Seattle Children's Hospital
Lymphoma, Neuroblastoma
Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
This research study is evaluating a novel drug called CUDC-907 as a possible treatment for resistant (refractory) pediatric solid tumors (including neuroblastoma), lymphoma, or brain tumors.
- Conditions
- Lymphoma, Neuroblastoma, Brain Tumor, Solid Tumor
- Trial name
- NCT02909777
- Testing
- CUDC-907
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Dana-Farber Cancer Institute